Published: 23 May 2024
Author(s): Ilaria Bassi, Stefania Pastorello, Aldo Guerrieri, Gilda Giancotti, Anna Maria Cuomo, Chiara Rizzelli, Maria Coppola, Danila Valenti, Stefano Nava
Section: Original Article

Idiopathic Pulmonary Fibrosis (IPF) is a relentlessly progressive fibrotic interstitial lung disease (ILD) with an unfavourable prognosis1. The median survival is 3 to 5 years form the time of diagnosis, but two antifibrotic agents, namely Nintedanib and Pirfenidone, have been shown to slow the decline of lung function (without any significant impact on quality-of-life (QoL)) [1,2]. IPF manifests as an unpredictable trajectory, wherein certain individuals undergo prolonged phases of gradual and progressive deterioration, while others are prone to acute exacerbations [1]; consequently, healthcare providers, patients, and caregivers frequently struggle to discern the variable nature of the disease's progression, leading to elevated levels of stress and anxiety [3].

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.